Web Exclusives
Web Exclusives — January 15, 2020
In an updated analysis of 134 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who were treated with acalabrutinib monotherapy, more than 90% were still responding after 41 months of treatment. Read More ›
Web Exclusives — January 15, 2020
Patients with chronic lymphocytic leukemia or mantle-cell lymphoma who were started on acalabrutinib in the United States had high rates of comorbid hypertension and other hematologic malignancies, and about two-thirds received prior ibrutinib. Read More ›
Web Exclusives — January 15, 2020
In shared decision-making, patients communicate their preferences and values to their healthcare team when treatment decisions are made. Patients who take an active role in the process tend to be more satisfied with their quality of care. Read More ›
Web Exclusives — January 15, 2020
Oral medications are being used increasingly in cancer treatment plans and are more convenient to take compared with medications administered in the doctor’s office or hospital. Oral treatments, however, have their own set of challenges that require effective communication between the patient and the healthcare team. Read More ›
Web Exclusives — December 9, 2019
Chimeric antigen receptor (CAR) T-cell therapy could soon expand into chronic lymphocytic leukemia (CLL). Early clinical trials have shown responses in patients with CLL refractory to other therapies. Predicting which patients will respond is key to advancing CAR T-cell therapy into CLL. Read More ›
Web Exclusives — December 9, 2019
Targeted therapy is at the forefront of chronic lymphocytic leukemia (CLL) treatment. In many cases, targeted agents offer superior outcomes to chemotherapy, with more manageable side effects. Multiple targeted therapy options are available, and some choices depend on certain molecular markers. Read More ›
Web Exclusives — December 9, 2019
Cytogenetic testing is used to identify genomic aberrations in patients with chronic lymphocytic leukemia (CLL). It estimates a patient’s outcomes and can predict response to certain therapies, and therefore is recommended for all patients with CLL at diagnosis. Read More ›
Web Exclusives — December 9, 2019
A new study presented at a major medical meeting showed that fewer patients with treatment-naïve chronic lymphocytic leukemia (CLL) who were treated with acalabrutinib alone or in combination with obinutuzumab had disease progression or died compared with a group of patients treated with the combination of obinutuzumab and chemotherapy. Read More ›
Web Exclusives — December 9, 2019
A 3-drug regimen of acalabrutinib, venetoclax, and obinutuzumab was highly effective in removing all traces of disease from the bone marrow of patients with chronic lymphocytic leukemia, according to study results presented at the American Society of Hematology annual meeting. Read More ›
Web Exclusives — December 4, 2019
There are a number of excellent organizations providing resources and support to you as a patient with ovarian cancer or a caregiver. Read More ›